CTOs on the Move

Alsius Corporation

www.alsius.com

 
Alsius Corporation (Alsius) is a commercial-stage medical device company that develops, manufactures and sells products to precisely control patient temperature in hospital critical care settings. The Company operates through its wholly owned subsidiary,
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.alsius.com
  • 15770 Laguna Canyon Rd Ste 150
    Irvine, CA USA 92618
  • Phone: 949.453.0150

Executives

Name Title Contact Details

Similar Companies

Horizon Ag-Products

Horizon Ag-Products, LP is a science and research-driven producer of innovative plant health solutions. We specialize in naturally-derived plant health products for the global agricultural market. Horizon Ag-Products is not a fertilizer company. We mak...

Bellus Health

BELLUS Health is a clinical stage biotechnology company developing novel therapeutics for the treatment of chronic cough and other chronic disorders triggered by hypersensitization.

Alfa Scientific Designs

Alfa Scientific Designs, Inc is a Poway, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Twentyeight-Seven Therapeutics

Twentyeight-Seven Therapeutics is a focused on the modulation of functional non-coding RNA (ncRNA) to treat cancer and other human diseases.

Minaris Advanced Therapies

Minaris Regenerative Medicine is a global Contract Development and Manufacturing Organization (CDMO) with over 25 years of experience in cell and gene therapies. The company operates advanced facilities across North America, Europe, and Asia, providing comprehensive solutions for advanced therapy medicinal products (ATMPs). Minaris specializes in clinical and commercial manufacturing, process development, and technology transfer, ensuring compliance with regulatory standards in the U.S., EU, and Japan. The company offers a range of services, including GMP manufacturing for cell therapies, technology transfer, and clinical development support for Phase I-III trials. Minaris has successfully completed over 100 technology transfers and has recently commercialized LYFGENIA, a gene therapy for sickle cell disease. With a focus on collaboration, Minaris serves over 180 biotech and pharmaceutical clients, providing tailored solutions for their specific needs in regenerative medicine. Its facilities include expanded cleanroom capacity and analytical labs to support large-scale production.